CN119798435A - 与lrp5蛋白结合的抗体及使用方法 - Google Patents

与lrp5蛋白结合的抗体及使用方法 Download PDF

Info

Publication number
CN119798435A
CN119798435A CN202411353225.5A CN202411353225A CN119798435A CN 119798435 A CN119798435 A CN 119798435A CN 202411353225 A CN202411353225 A CN 202411353225A CN 119798435 A CN119798435 A CN 119798435A
Authority
CN
China
Prior art keywords
lrp5
antibody
cdr
amino acid
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411353225.5A
Other languages
English (en)
Chinese (zh)
Inventor
萨奇德夫·西杜
潘国华
尼什·帕特尔
詹森·莫法特
斯蒂法尼·安格斯
贾勒特·亚当斯
贾加特·R·朱努图拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antola Clinic
Original Assignee
Antola Clinic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antola Clinic filed Critical Antola Clinic
Publication of CN119798435A publication Critical patent/CN119798435A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202411353225.5A 2019-08-14 2020-08-14 与lrp5蛋白结合的抗体及使用方法 Pending CN119798435A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962886913P 2019-08-14 2019-08-14
US62/886,913 2019-08-14
PCT/CA2020/051119 WO2021026665A1 (en) 2019-08-14 2020-08-14 Antibodies that bind to lrp5 proteins and methods of use
CN202080072086.2A CN114599679B (zh) 2019-08-14 2020-08-14 与lrp5蛋白结合的抗体及使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080072086.2A Division CN114599679B (zh) 2019-08-14 2020-08-14 与lrp5蛋白结合的抗体及使用方法

Publications (1)

Publication Number Publication Date
CN119798435A true CN119798435A (zh) 2025-04-11

Family

ID=74570326

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411353225.5A Pending CN119798435A (zh) 2019-08-14 2020-08-14 与lrp5蛋白结合的抗体及使用方法
CN202080072086.2A Active CN114599679B (zh) 2019-08-14 2020-08-14 与lrp5蛋白结合的抗体及使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080072086.2A Active CN114599679B (zh) 2019-08-14 2020-08-14 与lrp5蛋白结合的抗体及使用方法

Country Status (10)

Country Link
US (1) US20230183336A1 (https=)
EP (1) EP4013791A4 (https=)
JP (1) JP7840842B2 (https=)
KR (1) KR20220078568A (https=)
CN (2) CN119798435A (https=)
AU (1) AU2020329092A1 (https=)
CA (1) CA3147827A1 (https=)
IL (1) IL290509A (https=)
MX (1) MX2022001947A (https=)
WO (1) WO2021026665A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023250402A2 (en) * 2022-06-22 2023-12-28 Antlera Therapeutics Inc. Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
WO2022212429A1 (en) * 2021-03-31 2022-10-06 Sachdev Sidhu Anti-viral compositions for rift valley fever virus infections and methods of using same
EP4547713A2 (en) * 2022-06-30 2025-05-07 The University of Chicago Cd73 (nt5e) targeting polypeptides

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004261980A1 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody CDR polypeptide sequences with restricted diversity
US20070149496A1 (en) * 2003-10-31 2007-06-28 Jack Tuszynski Water-soluble compound
US8790650B2 (en) * 2011-04-28 2014-07-29 Vanderbilt University Methods of using an antibody to inhibit WNT-mediated cardiac remodeling
US9200072B2 (en) * 2012-01-18 2015-12-01 Genentech Inc. Anti-LRP5 antibodies and methods of use
US20190194314A1 (en) * 2012-12-21 2019-06-27 Stowers Institute For Medical Research Antibodies for modulating binding between lrp and wise
US10294294B2 (en) * 2015-09-10 2019-05-21 Albert Einstein College Of Medicine Synthetic antibodies to BAX and uses thereof
UA122079C2 (uk) * 2015-12-04 2020-09-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Поліпептид, що специфічно зв'язується з lrp5 і lrp6
CA3077518C (en) * 2016-09-07 2021-10-19 Frederic Fellouse Synthetic antibodies against vegf and their uses
EP3630816B1 (en) * 2017-05-31 2024-03-20 Boehringer Ingelheim International GmbH Polypeptides antagonizing wnt signaling in tumor cells
EP3700930A1 (en) * 2017-10-25 2020-09-02 The Regents of the University of California Antibodies against cdcp1 for the treatment and detection of cancer
CA3080120C (en) * 2017-10-27 2023-11-21 New York University Anti-galectin-9 antibodies and uses thereof
CN111699003B (zh) 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
JP7550647B2 (ja) * 2018-02-14 2024-09-20 アントレラ セラピューティクス インコーポレイテッド Ｗｎｔシグナル伝達を活性化する多価結合分子およびその使用
US10640562B2 (en) * 2018-07-17 2020-05-05 Mcmaster University T cell-antigen coupler with various construct optimizations
CA3111087A1 (en) * 2018-08-29 2020-03-05 Nanjing Legend Biotech Co., Ltd. Anti-mesothelin chimeric antigen receptor (car) constructs and uses thereof

Also Published As

Publication number Publication date
US20230183336A1 (en) 2023-06-15
CN114599679A (zh) 2022-06-07
EP4013791A1 (en) 2022-06-22
WO2021026665A1 (en) 2021-02-18
CN114599679B (zh) 2024-10-18
EP4013791A4 (en) 2024-01-24
JP7840842B2 (ja) 2026-04-06
IL290509A (en) 2022-04-01
CA3147827A1 (en) 2021-02-18
KR20220078568A (ko) 2022-06-10
MX2022001947A (es) 2022-06-14
AU2020329092A1 (en) 2022-03-31
JP2022544308A (ja) 2022-10-17

Similar Documents

Publication Publication Date Title
JP6936784B2 (ja) グリコシル化ｐｄ−ｌ１に特異的な抗体およびその使用方法
TWI526223B (zh) 人化ａｘｌ抗體類
TW202227132A (zh) 使用抗ｐｄ－１抗體與抗ｃｔｌａ－４抗體之組合以治療肺癌
CN114599679B (zh) 与lrp5蛋白结合的抗体及使用方法
KR20150032075A (ko) Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제
Katoh et al. Claudin 1, 4, 6 and 18 isoform 2 as targets for the treatment of cancer
JP7075135B2 (ja) 増殖因子を標的とする二機能性分子を使用したがんの治療方法
US20220213216A1 (en) Bispecific antibody with double her2 sites for tumor immunotherapy
CN114981304B (zh) 与lrp6蛋白结合的抗体及使用方法
IL323270A (en) Antibody against PTK7 and its uses
CN104853756A (zh) 利用netrin-1干扰药物和化疗药物的联合治疗
CN114616246B (zh) 卷曲受体抗体及其用途
RU2832155C2 (ru) Антитела, которые связываются с белками lrp5, и способы применения
WO2022075482A1 (ja) がん治療用医薬
WO2026067794A1 (en) Trispecific antibodies and uses thereof
HK40115552A (zh) 抗ptk7抗体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination